U.S. Patent and Trademark Office (PTAB)

The U.S. Patent and Trademark Office's Patent Trial and Appeal Board (PTAB) is an administrative tribunal headquartered in Alexandria, Virginia, with satellite offices in Dallas, Denver, Detroit, and San Jose. It serves as a specialized forum for resolving patentability disputes, distinct from federal district courts. Decisions from the PTAB are appealable to the U.S. Court of Appeals for the Federal Circuit. The PTAB handles a substantial volume of post-grant review proceedings, including inter partes reviews (IPR), post-grant reviews (PGR), and covered business method (CBM) reviews, in addition to appeals from patent examiner rejections. It has become a pivotal and often faster alternative for challenging patent validity compared to traditional district court litigation.

The PTAB has a reputation as an efficient venue for patent validity challenges. While not a "rocket docket" in the district court sense, its administrative trial proceedings are typically faster than federal court litigation. Historically, the PTAB has been characterized by high patent invalidation rates, with 70% of all challenged claims found invalid in final written decisions in FY2024, an increase from 55% in 2019. This rate reached 71% for the first two quarters of 2024. However, institution rates for post-grant petitions have seen fluctuations, decreasing from 68% in FY2024 to 50% in FY2025, and further to 37% in the first two months of FY2026, partly due to evolving discretionary denial policies by the USPTO Director. The PTAB employs the Phillips standard for claim construction, consistent with federal district courts, and conducts bench trials before panels of Administrative Patent Judges rather than jury trials.

The PTAB's procedures are governed by the America Invents Act (AIA) and a comprehensive Trial Practice Guide (TPG), which outlines requirements for petition and motion practice, discovery, testimony, and evidence submission. Recent guidance has addressed issues such as the filing of multiple petitions and the submission of testimonial evidence. Effective September 1, 2025, PTAB hearings are generally conducted in person at USPTO locations, though remote participation may be requested for good cause. A significant ruling impacting the PTAB was the 2021 Supreme Court decision in United States v. Arthrex, Inc., which addressed the constitutional appointment of Administrative Patent Judges and required increased supervision by the USPTO Director over their decisions. A currently tracked case before the PTAB is Sarepta Therapeutics, Inc. v. Genzyme Corp., which is awaiting an institution decision.

The PTAB comprises over 100 Administrative Patent Judges (APJs) who are appointed by the Secretary of Commerce and possess both legal and technical training, often with extensive experience in patent law. The current Chief Judge for the Patent Trial and Appeal Board is Kalyan K. Deshpande. These judges, who typically hear cases in panels of three, are central to the PTAB's role in reviewing patentability decisions and adjudicating post-grant challenges. Prominent former APJs include individuals like Tim Fink, James Moore, and Scott Weidenfeller, who have contributed to PTAB policy and practice.